ImmunOs Therapeutics is a technology company.
Our mission at ImmunOs Therapeutics AG is to develop novel therapeutics that improve the lives of patients with serious diseases.
ImmunOs Therapeutics has raised $99.3M across 4 funding rounds.
ImmunOs Therapeutics has raised $99.3M in total across 4 funding rounds.
# ImmunOs Therapeutics: A Biotechnology Pioneer, Not a Technology Company
ImmunOs Therapeutics is not a technology company—it is a clinical-stage biotechnology company focused on discovering and developing novel immunomodulatory therapeutics for cancer and inflammatory diseases[3]. The distinction matters: while it employs cutting-edge scientific approaches, its core business is drug development, not software, hardware, or digital platforms.
ImmunOs Therapeutics is a Swiss biotech company originally spun out from the University of Zurich and University of Basel[4]. The company develops next-generation human immunomodulatory proteins that target the innate immune system to enhance anti-tumor responses and treat inflammatory conditions[4]. Its mission centers on improving patient outcomes in serious diseases by leveraging advances in understanding immune system modulation.
The company operates in two primary therapeutic areas: immune-oncology and inflammatory diseases[1]. Rather than building technology platforms for external use, ImmunOs develops proprietary biologics—complex protein-based drugs—designed to modulate specific immune checkpoints on various cell types involved in cancer and inflammation[1].
ImmunOs emerged from academic research at two leading Swiss universities, positioning it within the growing wave of university-derived biotech spinouts[4]. The company's scientific foundation rests on HLA open conformer modulation—a novel approach to targeting innate immunity that distinguishes it from established immunotherapy strategies like PD-1 antibodies[4].
The company achieved early validation through significant funding milestones. It raised CHF 15 million in Series A financing co-led by Pfizer Ventures and BioMedPartners, with board participation from experienced pharma executives including former Novartis leadership[4]. Subsequent funding rounds—including a CHF 71 million Series B and a USD 74 million round—demonstrate investor confidence in its clinical advancement trajectory[2].
ImmunOs operates within the expanding immunotherapy sector, where understanding of the innate immune system's role in cancer treatment remains an emerging frontier[4]. While checkpoint inhibitors targeting the adaptive immune system (like PD-1/PD-L1 inhibitors) have become standard-of-care, many patients show limited response or develop resistance. ImmunOs addresses this gap by targeting innate immunity—a less crowded but scientifically promising space.
The company represents Switzerland's growing strength in biotech innovation, recognized among the country's most promising scale-ups[2]. Its success reflects broader trends: the maturation of immunotherapy as a cancer treatment modality, increasing investor appetite for deep-science biotech, and the strategic value of innate immunity as a therapeutic target.
ImmunOs stands at a critical inflection point. With substantial funding secured and clinical trials underway, the company's trajectory depends on demonstrating clinical efficacy in its lead programs. Success could validate innate immunity modulation as a meaningful therapeutic approach, potentially opening new combination therapy opportunities alongside existing immunotherapies.
The company's partnership with Pfizer—both as an investor and through board representation—suggests potential pathways for clinical development, regulatory navigation, and eventual commercialization. As the immunotherapy landscape matures and competition intensifies, ImmunOs' differentiated mechanism and dual-indication strategy position it to capture value in an increasingly sophisticated market for cancer and inflammatory disease treatments.
ImmunOs Therapeutics has raised $99.3M in total across 4 funding rounds.
ImmunOs Therapeutics's investors include Angel investor, Pfizer Venture Investments, Balaji Srinivasan, Samsara BioCapital, BackBone Ventures, Daniel Vasella.
ImmunOs Therapeutics has raised $99.3M across 4 funding rounds. Most recently, it raised $11.0M Series C in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $11.0M Series C | Angel investor, Pfizer Venture Investments, Balaji Srinivasan | |
| Jun 1, 2022 | $73.0M Series B | Angel investor, Pfizer Venture Investments, Samsara BioCapital, Balaji Srinivasan | |
| Dec 1, 2019 | $15.0M Series A | Angel investor, BackBone Ventures, Pfizer Venture Investments, Samsara BioCapital, Balaji Srinivasan, Daniel Vasella | |
| Oct 1, 2014 | $310K Seed | BackBone Ventures |